These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 19886115)

  • 1. Pharmacoeconomics: principles and relevance to the activities of drug and therapeutics committees.
    Hughes D; Reynolds DJ
    Clin Med (Lond); 2009 Oct; 9(5):490-2. PubMed ID: 19886115
    [No Abstract]   [Full Text] [Related]  

  • 2. [Hospital essential drugs in Africa. An example of pharmacoeconomic research].
    Meillon C; Stum N; Cuisinier-Raynal JC
    Dakar Med; 1996; Spec No():19-20. PubMed ID: 14520980
    [No Abstract]   [Full Text] [Related]  

  • 3. Application of pharmacoeconomics to formulary management in a health system setting.
    Studdert AL; Gong CL; Srinivas S; Chin AL; Deresinski S
    Am J Health Syst Pharm; 2019 Feb; 76(6):381-386. PubMed ID: 31361838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pharmacoeconomics and formulary management collaborative project to teach decision analysis principles.
    Cavanaugh TM; Buring S; Cluxton R
    Am J Pharm Educ; 2012 Aug; 76(6):115. PubMed ID: 22919091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The power of pharmacoeconomics.
    Healthc Exec; 2000; 15(1):44-5. PubMed ID: 11067028
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacoeconomics and the quality of decision-making by pharmacy and therapeutics committees.
    Langley PC
    Am J Health Syst Pharm; 1995 Jul; 52(14 Suppl 3):S24-6. PubMed ID: 7552914
    [No Abstract]   [Full Text] [Related]  

  • 7. Hospital drug and therapeutics committees in Australia: is there a role for economic evaluation at the institutional level?
    Gallego G
    Int J Clin Pharm; 2011 Dec; 33(6):895-7. PubMed ID: 21922271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Lipid-lowering drugs, cost-effectiveness data, and the formulary system: a health systems perspective.
    Kessler JM
    Am Heart J; 1999 May; 137(5):S111-4. PubMed ID: 10220610
    [No Abstract]   [Full Text] [Related]  

  • 9. Praxis makes perfect?
    Fins JJ
    Hastings Cent Rep; 1993; 23(5):16-9. PubMed ID: 7710462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A call for fairness in formulary decisions.
    Levinson W; Laupacis A
    Arch Intern Med; 2006 Jan; 166(1):16-8. PubMed ID: 16401806
    [No Abstract]   [Full Text] [Related]  

  • 11. [Pharmacoeconomics studies in specialized care: the principles, methods and practical applications].
    Soto Alvarez J
    An Med Interna; 1999 Jan; 16(1):41-6. PubMed ID: 10089651
    [No Abstract]   [Full Text] [Related]  

  • 12. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies: a health system perspective on thrombolytic therapy for acute myocardial infarction.
    Lewandowski CA; Kahler J
    Am Heart J; 1999 May; 137(5):S94-6. PubMed ID: 10220607
    [No Abstract]   [Full Text] [Related]  

  • 13. Barriers to implementing pharmacoeconomics: interview study.
    Alefan Q; Hamdouni E; Alhamad H; Mukattash T; Rascati K
    Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):93-104. PubMed ID: 32394752
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of pharmacoeconomic data in making hospital formulary decisions.
    Odedina FT; Sullivan J; Nash R; Clemmons CD
    Am J Health Syst Pharm; 2002 Aug; 59(15):1441-4. PubMed ID: 12166044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving pharmacy and therapeutics committee operations.
    Cohen MR; Klapp D; Miller KB; Shaffer VL; Slotfeldt M; Miller DE
    Am J Hosp Pharm; 1984 Sep; 41(9):1767-77. PubMed ID: 6496511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing conflicts of interest in pharmacy and therapeutics committees: A proposal for multicentre formulary development.
    Friesen P; Caplan AL; Miller JE
    J Clin Pharm Ther; 2020 Apr; 45(2):249-255. PubMed ID: 31657022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacoeconomics: a new activity for the drug adviser in primary care?].
    Soto Alvarez J
    Aten Primaria; 1999 Mar; 23(4):250, 252. PubMed ID: 10333612
    [No Abstract]   [Full Text] [Related]  

  • 18. Multi-tier drugs assessment in a decentralised health care system. The Italian case-study.
    Jommi C; Costa E; Michelon A; Pisacane M; Scroccaro G
    Health Policy; 2013 Oct; 112(3):241-7. PubMed ID: 23850166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulary management in the Department of Defense.
    Trice S; Devine J; Mistry H; Moore E; Linton A
    J Manag Care Pharm; 2009 Mar; 15(2):133-46. PubMed ID: 19236127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Health system perspective regarding glycoprotein IIb/IIIa inhibitor therapy.
    Schrogie JJ
    Am Heart J; 1999 May; 137(5):S126-8. PubMed ID: 10220614
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.